Jiang Guoqiang, Zhang Bei B
Department of Metabolic Disorders and Molecular Endocrinology, Merck Research Laboratory, Rahway, New Jersey 07065, USA.
Am J Physiol Endocrinol Metab. 2003 Apr;284(4):E671-8. doi: 10.1152/ajpendo.00492.2002.
As a counterregulatory hormone for insulin, glucagon plays a critical role in maintaining glucose homeostasis in vivo in both animals and humans. To increase blood glucose, glucagon promotes hepatic glucose output by increasing glycogenolysis and gluconeogenesis and by decreasing glycogenesis and glycolysis in a concerted fashion via multiple mechanisms. Compared with healthy subjects, diabetic patients and animals have abnormal secretion of not only insulin but also glucagon. Hyperglucagonemia and altered insulin-to-glucagon ratios play important roles in initiating and maintaining pathological hyperglycemic states. Not surprisingly, glucagon and glucagon receptor have been pursued extensively in recent years as potential targets for the therapeutic treatment of diabetes.
作为胰岛素的一种对抗调节激素,胰高血糖素在维持动物和人类体内葡萄糖稳态方面发挥着关键作用。为了升高血糖,胰高血糖素通过多种机制协同作用,增加糖原分解和糖异生,减少糖原合成和糖酵解,从而促进肝脏葡萄糖输出。与健康受试者相比,糖尿病患者和动物不仅胰岛素分泌异常,胰高血糖素分泌也异常。高胰高血糖素血症以及胰岛素与胰高血糖素比值的改变在引发和维持病理性高血糖状态中起重要作用。不出所料,近年来,胰高血糖素和胰高血糖素受体作为糖尿病治疗的潜在靶点受到了广泛关注。